Skin Cancer Face
9
2
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
Comparing Numbing Techniques in Mohs Micrographic Surgery
Vellus Hair Loss as a Marker for Peri-ocular Malignancy
CApecitabine Prior to TUmor Resection in Ent Oncology (CAPTURE)
Tranexamic Acid in Nasal Mohs Reconstruction
Nasal Iodine Swab Versus Oral Antibiotic to Prevent Surgical Site Infection After Undergoing Mohs Micrographic Surgery
Exploratory Prospective of Experienced by Patients in the Surgery of Skin Cancers of the Face in Interventional Dermatology Department
Topical Antibiotic Prophylaxis for Eyelids
Correlation of Early Postoperative Scar Appearance With Long-term Scar Outcomes
Buddy Relationships in DermatoloGic Excisions for Skin Cancer